Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 3, 2007, Pages 473-480

  Schildkraut, Joellen M ^a   Murphy, Susan K ^b   Palmieri, Rachel T ^c   Iversen, Edwin ^a   Moorman, Patricia G ^a   Huang, Zhiqing ^b   Halabi, Susan ^a   Calingaert, Brian ^a   Gusberg, Alison ^b   Marks, Jeffrey R ^a   Berchuck, Andrew ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA DETERMINATION; DNA POLYMORPHISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RACE DIFFERENCE; TRINUCLEOTIDE REPEAT;

ADULT; AFRICAN AMERICANS; AGED; ALLELES; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; NORTH CAROLINA; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; POPULATION SURVEILLANCE; RECEPTORS, ANDROGEN; REGISTRIES; RISK FACTORS; TRINUCLEOTIDE REPEATS;

EID: 34147186189     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0868     Document Type: Article

References (36)

1. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998; 90:1774-86.
2. Modugno F. Ovarian cancer and polymorphisms in the androgen and progesterone receptor genes:a HuGE review. Am J Epidemiol 2004;159: 319-35.
3. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-α and - β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A 1999;96: 5722-7.
4. Kuhnel R, de Graaff J, Rao BR, Stolk JG. Androgen receptor predominance in human ovarian carcinoma. J Steroid Biochem 1987;26:393-7.
5. Chadha S, Rao BR, Slotman BJ, van Vroonhoven CC, van der Kwast TH. An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol 1993;24:90-5.
6. Slotman BJ, Baak JP, Rao BR. Correlation between nuclear DNA content and steroid receptor status in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 199138:221-7.
7. Edmondson RJ, Monaghan JM. The epidemiology of ovarian cancer. Int J Gynecol Cancer 2001;11:423-9.
8. Hoyo C, Berchuck A, Halabi S, et al. Anthropometric measurements and epithelial ovarian cancer risk in African American and White women. Cancer Causes Control 2005;16:955-63.
9. Mink PJ, Folsom AR, Sellers TA, Kushi LH. Physical activity, waist-to-hip ratio, and other risk factors for ovarian cancer:a follow-up study of older women. Epidemiology 1996;7:38-45.
10. Schildkraut JM, Schwingl P, Bastos E, Evanoff A, Hughes C. Epithelial ovarian cancer risk among women with polycystic ovarian disease. Obstet Gynecol 1996;88:554-9.
11. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995;274: 1926-30.
12. Kadouri L, Easton DF, Edwards S, et al. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer 2001;85:36-40.
13. Sleddens HF, Oostra BA, Brinkmann AO, Trapman J. Trinucleotide repeat polymorphism in the androgen receptor gene (AR). Nucleic Acids Res 1992; 20:1427.
14. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22:3181-6.
15. Nelson KA, Witte JS. Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol 2002;155:883-90.
16. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 1992;12:241-53.
17. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000;92:2009-17.
18. Sleddens HF, Oostra BA, Brinkmann AO, Trapman J. Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. Hum Mol Genet 1993;2:493.
19. Ding Y, Tong M, Liu S, Moscow JA, Tai HH. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 2005;26:65-72.
20. Terry KL, De Vivo I, Titus-Ernstoff L, Sluss PM, Cramer DW. Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol 2005;161:442-51.
21. Santarosa M, Bidoli E, Gallo A, Steffan A, Boiocchi M, Viel A. Polymorphic CAG repeat length within the androgen receptor gene:identification of a subgroup of patients with increased risk of ovarian cancer. Oncol Rep 2002; 9:639-44.
22. Spurdle AB, Chen X, Abbazadegan M, et al. CYP17 promotor polymorphism and ovarian cancer risk. Int J Cancer 2000;86:436-9.
23. Menin C, Banna GL, De Salvo G, et al. Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. Cancer Lett 2001;168:31-6.
24. Irvine RA, Yu MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995;55:1937-40.
25. Barry D, Hartigan JA. Bayesian Analysis for Change Point Problems. J Am Stat Assoc 1993;88:309-19.
26. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000;155:945-59.
27. Spurdle AB, Webb PM, Chen X, et al. Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer. Int J Cancer 2000;87:637-43.
28. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-61.
29. Mifsud A, Ramirez S, Yong EL. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J Clin Endocrinol Metab 2000;85:3484-8.
30. Sawaya ME, Shalita AR. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J Cutan Med Surg 1998;3:9-15.
31. Buchanan G, Yang M, Cheong A, et al. Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet 2004;13:1677-92.
32. Pettaway CA. Racial differences in the androgen/androgen receptor pathway in prostate cancer. J Natl Med Assoc 1999;91:653-60.
33. Hsing AW, Gao YT, Wu G, et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk:a population-based case-control study in China. Cancer Res 2000;60:5111-6.
34. Gsur A, Preyer M, Haidinger G, et al. Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis 2002;23:1647-51.
35. Balic I, Graham ST, Troyer DA, et al. Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol 2002;168:2245-8.
36. Li C, Gronberg H, Matsuyama H, et al. Difference between Swedish and Japanese men in the association between AR CAG repeats and prostate cancer suggesting a susceptibility-modifying locus overlapping the androgen receptor gene. Int J Mol Med 2003;11:529-33.